Trial · NCT00658736
Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis
NCT00658736, Phase 3, Completed, The Cleveland Clinic; results first posted 2017-06-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis. Trials, record NCT00658736. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00658736
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis
- NCT number
- NCT00658736
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 40 participants, actual
- Lead sponsor
- The Cleveland Clinic
- Conditions
- Chronic Pancreatitis
- Interventions
- Triamcinolone, Bupivicaine alone
- First posted
- 2008-04-15
- Last updated
- 2017-06-14
- Results first posted
- 2017-06-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pain Disability Index | 1 month after block | The Pain Disability Index (PDI) measures patients' responses of the extent to which pain limits their abilities to carry out everyday tasks. The index is scored from 0 (no limitation) to 70 (severe limitation). A decrease in score of 10 points or more is regarded as indicating significant improvement in the ability to carry out daily activities. |
| Secondary | Change From Baseline in Quality of Life Score at 1 Month - SF12 Physical Component | 1 month | The SF12 survey measures patients' impressions of their level of health and well-being. The results are reported as two scores: A physical component and a mental component, each of which is reported on a scale of 0 (lowest level of health) to 100 (excellent health). Scores that increase from baseline indicate an improvement in patients' feelings of well-being. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Pain Disability Index | 1 month after block | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change From Baseline in Quality of Life Score at 1 Month - SF12 Physical Component | 1 month | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Pain Disability Index | Bupivicaine and Triamcinolone | 3 | Participants | ||
| Change in Pain Disability Index | Bupivicaine Alone | 3 | Participants | ||
| Change From Baseline in Quality of Life Score at 1 Month - SF12 Physical Component | Bupivicaine and Triamcinolone | -0.2 | Standard Deviation 7.5 | units on a scale | |
| Change From Baseline in Quality of Life Score at 1 Month - SF12 Physical Component | Bupivicaine Alone | 1.7 | Standard Deviation 8.8 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bupivicaine Alone | 19 | |
| Overall Study | STARTED | Bupivicaine Plus Triamcinolone | 21 | |
| Overall Study | COMPLETED | Bupivicaine Alone | 13 | |
| Overall Study | COMPLETED | Bupivicaine Plus Triamcinolone | 19 | |
| Overall Study | NOT COMPLETED | Bupivicaine Alone | 6 | |
| Overall Study | NOT COMPLETED | Bupivicaine Plus Triamcinolone | 2 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension urgency | Vascular disorders | Bupivicaine and Triamcinolone | 0 | 21 | 0 |
| other | Hypertension urgency | Vascular disorders | Bupivicaine Alone | 1 | 19 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Bupivicaine and Triamcinolone | 3 | 21 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Bupivicaine Alone | 1 | 19 | 1 |
| other | Gastric hematoma | Gastrointestinal disorders | Bupivicaine and Triamcinolone | 1 | 21 | 1 |
| other | Gastric hematoma | Gastrointestinal disorders | Bupivicaine Alone | 0 | 19 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bupivicaine and Triamcinolone | ||
| Total, all-cause mortality | Bupivicaine Alone | ||
| Total, other adverse events | Bupivicaine and Triamcinolone | 4 | 21 |
| Total, other adverse events | Bupivicaine Alone | 2 | 19 |
| Total, serious adverse events | Bupivicaine and Triamcinolone | 0 | 21 |
| Total, serious adverse events | Bupivicaine Alone | 0 | 19 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Bupivicaine and Triamcinolone vs Bupivicaine Alone: Change in Pain Disability Index | Trial comparisons |
| Bupivicaine and Triamcinolone vs Bupivicaine Alone: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00658736
GET https://conductscience.org/api/trials/v1/NCT00658736/registered